İLKER DEVRİM, Bengü DEMİRAĞ, Yöntem YAMAN, SÜLEYMAN NURİ BAYRAM, Fatih ÖZDEMİR, Ahu KARA, Gülcihan ÖZEK, Yüce AYHAN, Gamze GÜLFİDAN, Yeşim OYMAK, Canan VERGİN

A 7-year study of the distribution of nosocomial candidemia in children with cancer

Devrim İ, Demirağ B, Yaman Y, Bayram N, Özdemir F, Kara A, Özek G, Ayhan Y, Gülfidan G, Oymak Y, Vergin C. A 7-year study of the distribution of nosocomial candidemia in children with cancer. Turk J Pediatr 2015; 57: 225-229. Candidemia is an important cause of morbidity and mortality in cancer patients. The incidence of candidemia has been reported to have shifted toward nonalbicans species. The aim of this study was to determine the distribution of Candida species resulting in bloodstream infections or catheter-related blood stream infections (CRBSIs) in pediatric hematology-oncology (PHO) patients over a 7-year-period. Medical and computerized microbiology laboratory records of all positive blood fungal cultures during the study period were analyzed retrospectively. The ratio of non-albicans Candida species (81.4%) was nearly four times higher than that of C. albicans candidemia (18.5%). Overall, C. parapsilosis caused the majority (61.4%) of candidemia episodes, followed by C. tropicalis (14.8%), C. famata (2.9%), C. ciferrii (1.4%) and C. glabrata (0.7%). The rate of CRBSIs was significantly higher in C. parapsilosis candidemia. The overall rate of 30-day mortality in 135 candidemia episodes was 4.44%. Nearly half of the C. parapsilosis candidemia was associated with CRBSIs, suggesting its importance in PHO, in which several types of central venous catheters have been used.

PDF

___

1. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-1239.

2. Filioti J, Spiroglou K, Panteliadis CP, Roilides E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. Intensive Care Med 2007; 33: 1272-1283.

3. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-3259.

4. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J 2003; 22: 686-691.

5. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.

6. Méan M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 2008; 12: 204.

7. Kuzucu C, Durmaz R, Otlu B, Aktas E, Gulcan H, Cizmeci Z. Species distribution, antifungal susceptibility and clonal relatedness of Candida isolates from patients in neonatal and pediatric intensive care units at a medical center in Turkey. New Microbiol 2008; 31: 401-408.

8. Hinrichsen SL, Falcão E, Vilella TA, et al. [Candidemia in a tertiary hospital in northeastern Brazil]. [Article in Portuguese] Rev Soc Bras Med Trop 2008; 41: 394- 398.

9. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn Microbiol Infect Dis 2010; 68: 278-283.

10. Aydin F, Bayramoglu G, Guler NC, Kaklikkaya N, Tosun I. Bloodstream yeast infections in a university hospital in Northeast Turkey: a 4-year survey. Med Mycol 2011; 49: 316-319.

11. Cugno C, Cesaro S. Epidemiology, risk factors and therapy of candidemia in pediatric hematological patients. Pediatr Rep 2012; 4: e9.

12. Manno G, Scaramuccia A, Rossi R, Coppini A, Cruciani M. Trends in antifungal use and species distribution among Candida isolates in a large paediatric hospital. Int J Antimicrob Agents 2004; 24: 627-628.

13. Vento S, Cainelli F. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. Lancet Oncol 2003; 4: 595-604.

14. Lockhart PB, Sonis ST. Relationship of oral complications to peripheral blood leukocyte and platelet counts in patients receiving cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1979; 48: 21-28.

15. Durango H, Hernández M, Zapata C, et al. Colonización por especies de Candida en orofaringe y tracto gastrointestinal enniños. Infection 2002; 63: 156-161.

16. Posteraro B, Bruno S, Boccia S, et al. Candida parapsilosis bloodstream infection in pediatric oncology patients: results of an epidemiologic investigation. Infect Control Hosp Epidemiol 2004; 25: 641-645.

17. Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008; 21: 606-625.

18. Devrim I, Yaman Y, Demirağ B, et al. A single center's experience with Candida parapsilosis related longterm central venous access device infections: the port removal decision and its outcomes. Pediatr Hematol Oncol 2014; 31: 435-441.

19. Nakamura T, Takahashi H. Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia. J Infect Chemother 2006; 12: 132-138.

20. Ng KP, Saw TL, Na SL, Soo-Hoo TS. Systemic Candida infection in university hospital 1997-1999: the distribution of Candida biotypes and antifungal susceptibility patterns. Mycopathologia 2001; 149: 141-146.

21. Medrano DJ, Brilhante RS, Cordeiro RA, Rocha MF, Rabenhorst SH, Sidirm JJ. Candidemia in a Brazilian hospital: the importance of Candida parapsilosis. Rev Inst Med Trop Sao Paulo 2006; 48: 17-20.

22. De Carvalho Parahym AM, De Melo LR, De Morais VL, Neves RP. Candidiasis in pediatric patients with cancer interned in a university hospital. Braz J Microbiol 2009; 40: 321-324.

23. Mullen CA, Abd El-Baki H, Samir H, Tarrand JJ, Rolston KV. Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients. Support Care Cancer 2003; 11: 321-325.

24. Girmenia C, Martino P, De Bernadis F, et al. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996; 23: 506- 514.

25. Levy I, Rubin LG, Vasishtha S, Tucci V, Sood SK. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 1998; 26: 1086-1088.

26. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189.

27. Posteraro B, Bruno S, Boccia S, et al. Candida parapsilosis bloodstream infection in pediatric oncology patients: results of an epidemiologic investigation. Infect Control Hosp Epidemiol 2004; 25: 641-645.

28. Kaya Z, Gursel T, Kocak U, Aral YZ, Kalkanci A, Albayrak M. Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis. Pediatr Blood Cancer 2009; 52: 470-475.

29. Rosen GP, Nielsen K, Glenn S, Abelson J, Deville J, Moore TB. Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 2005; 27: 135-140.

30. Castagnola E, Cesaro S, Giacchino M, et al. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J 2006; 25: 634-639.

31. Mor M, Gilad G, Kornreich L, Fisher S, Yaniv I, Levy I. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer 2011; 56: 1092-1097.